WST
WEST PHARMACEUTICAL SERVICES INCPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Apr 23 ▲ West Pharmaceutical Services reported strong Q1 2026 results with re…
- Apr 27 ▼ 2 insiders sell $1.1M at $304.11
- May 11 ▼ West Pharmaceutical (WST) disclosed a material cybersecurity attack…
- May 27 ▼ Ro Khanna sold $1,001 - $15,000, last disclosed Jun 11
- Jun 30 ▲ 3 funds open new positions (13F)
- Jul 21 Dividend: West Declares Quarterly Dividend
- Jul 23 ▲ West Pharmaceutical Services reported Q2 2026 results that significa…
- Jul 23 ▲ West Pharmaceutical reported Q2 2026 net sales of $872.3M (+13.8% Yo…
- Sep 8 to Sep 15 ▼ 4 days of insider sells: $5.4M by 1 insider, avg $347.64
- Sep 22 ▲ Morgan Stanley upgrades
- Oct 29 ▲ West Pharmaceutical reported Q3 2026 net sales of $874.5M (+8.7% rep…
- Oct 29 ▲ West Pharmaceutical Services reported Q3 2026 adjusted-diluted EPS o…
Signal stack
Where each data set points today.
- InsidersBEARISH
2 insiders sold $6.6M.
- InstitutionsBULLISH
Q2 2026: 60 added (3 new), 35 trimmed or exited. Largest new: Boston Trust Walden $29.2M, Capitolis Liquid Global Markets $12.8M.
- AnalystsBULLISH
20 of 21 rate it Buy or better. Median target $480.00 (+15%).
- EstimatesFLAT
Current-quarter EPS estimate $2.270 → $2.284 over 90 days. 6 up, 2 down in 30 days.
- Short sellersSTEADY
Short interest −10.2% to 1.81M shares. 2.3 days to cover, ≈2.6% of shares.
- TrendUPTREND
9% above its 50-day average. New closing high $417.80 on Nov 16.
- SocialQUIET
No Reddit mentions this week. Last mention Oct 28.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| FMR LLC | DOUBLED | $1.3B |
| JACOBS LEVY EQUITY MANAGEMENT, INC | TRIM | $182.3M |
| STATE FARM MUTUAL AUTOMOBILE INSURANCE CO | ADD | $177.8M |
| APG Asset Management N.V. | TRIM | $176.0M |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | DOUBLED | $149.8M |
| Amundi | TRIM | $138.3M |
| UBS Group AG | ADD | $134.4M |
| Quantinno Capital Management LP | ADD | $110.6M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
21 analystsPrice is inside the target range. Median implies +15%.Targets as of Nov 16, 2026.
| Date | Firm | Rating |
|---|---|---|
| Oct 30, 2026 | Citigroup MAINTAIN | Buy |
| Oct 30, 2026 | TD Cowen MAINTAIN | Buy |
| Oct 30, 2026 | Barclays MAINTAIN | Overweight |
| Oct 30, 2026 | Evercore ISI Group MAINTAIN | Outperform |
| Oct 13, 2026 | TD Cowen MAINTAIN | Buy |
| Oct 7, 2026 | Barclays MAINTAIN | Overweight |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
HAUGEN JANET BRUTSCHEA Director Sep 30, 2026 | AWARD | $16.3K |
Favorite Annette F Sr. VP & Chief HR Officer Sep 15, 2026 | EXERCISE | $226.3K |
Favorite Annette F Sr. VP & Chief HR Officer Sep 15, 2026 | SELL | $921.3K |
Favorite Annette F Sr. VP & Chief HR Officer Sep 14, 2026 | EXERCISE | $224.1K |
Favorite Annette F Sr. VP & Chief HR Officer Sep 14, 2026 | SELL | $887.5K |
Favorite Annette F Sr. VP & Chief HR Officer Sep 11, 2026 | SELL | $862.5K |
Favorite Annette F Sr. VP & Chief HR Officer Sep 11, 2026 | EXERCISE | $224.1K |
Lagarde Michel President and CEO Sep 8, 2026 | AWARD | 13,879 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | $2.28 | $2.23–$2.32 | +0.5% | $825.2M |
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
17 filings · 5 bullish · 1 bearish · 11 neutral- NEUTRAL SC 13G/ANov 5, 2026
FMR LLC (Fidelity) filed an amended Schedule 13G reporting beneficial ownership of 5,962,737.88…
Fidelity's passive 8.5% stake is consistent with its role as a top institutional holder. No change in investment intent or activism signaled. Monitor future filings for any conversion to 13D, which…
- BULLISH 8-KOct 29, 2026
West Pharmaceutical reported Q3 2026 net sales of $874.5M (+8.7% reported, +11.9% organic) and…
The raised guidance and strong HVP Components growth (20.3% organic) signal sustained demand from biologics and GLP-1 customers. Monitor Q4 for continued margin expansion and any further updates on…
- BULLISH PRESS-RELEASEOct 29, 2026
West Pharmaceutical Services reported Q3 2026 adjusted-diluted EPS of $2.66, beating the $2.20…
The raised guidance and strong HVP Components growth (20.3% organic) signal sustained demand for high-value injectable solutions. Monitor the West Vantage segment's continued decline (-6.6% organic)…
- NEUTRAL 8-KOct 26, 2026
West Pharmaceutical Services entered into a new $950 million unsecured credit agreement on October…
Monitor the company's use of the new facility for acquisitions or share repurchases, which could increase leverage. The next quarterly filing will show the initial drawdown and any impact on the net…
All WST filing & press-release reports (17)
- SC 13G/A reportNov 5, 2026
- 8-K reportOct 29, 2026
- PRESS-RELEASE reportOct 29, 2026
- 8-K reportOct 26, 2026
- INST-CLUSTER reportOct 26, 2026
- 8-K reportJul 23, 2026
- PRESS-RELEASE reportJul 23, 2026
- PRESS-RELEASE reportJul 7, 2026
- 8-K reportMay 11, 2026
- CLUSTER reportApr 27, 2026
- CLUSTER reportApr 27, 2026
- CLUSTER reportApr 27, 2026
- CLUSTER reportApr 27, 2026
- CLUSTER reportApr 27, 2026
- CLUSTER reportApr 27, 2026
- 8-K reportApr 23, 2026
- DEFA14A reportMar 12, 2026